Pemphigus vulgaris successfully treated with ocrelizumab following rituximab allergy

Abstract

Pemphigus vulgaris (PV) is a rare autoimmune blistering disorder primarily treated with immunosuppressive agents. Rituximab, a chimeric anti-CD20 monoclonal antibody, is widely used as first-line therapy for PV.1 Anti-CD20 agents, associated biosimilars, and other B-cell depleting agents have also been reported to effectively treat PV.2,3 Ocrelizumab, a humanized anti-CD20 monoclonal antibody, has not been studied in PV. We describe a case of refractory PV successfully treated with ocrelizumab.